Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases.
It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020.
Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 1, 23 | -1.15 Decreased by -11.65% | -0.79 Decreased by -45.57% |
| Aug 2, 23 | -1.13 Decreased by -54.79% | -0.81 Decreased by -39.51% |
| Apr 27, 23 | -0.93 Decreased by -25.68% | -0.82 Decreased by -13.41% |
| Feb 15, 23 | -0.80 Increased by +15.79% | -1.04 Increased by +23.08% |
| Oct 27, 22 | -1.03 Increased by +36.02% | -0.96 Decreased by -7.29% |
| Jul 28, 22 | -0.73 Decreased by -55.32% | -0.86 Increased by +15.12% |
| Apr 28, 22 | -0.74 Decreased by -10.45% | -0.99 Increased by +25.25% |
| Feb 9, 22 | -0.95 Decreased by -205.56% | -0.83 Decreased by -14.46% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 648.65 M Increased by +27.11% | -215.79 M Decreased by -13.09% | Decreased by -33.27% Increased by +11.03% |
| Jun 30, 23 | 603.83 M Increased by +21.37% | -211.53 M Decreased by -56.89% | Decreased by -35.03% Decreased by -29.26% |
| Mar 31, 23 | 519.72 M Increased by +21.87% | -174.74 M Decreased by -28.02% | Decreased by -33.62% Decreased by -5.05% |
| Dec 31, 22 | 528.15 M Increased by +22.87% | -148.17 M Increased by +15.15% | Decreased by -28.05% Increased by +30.94% |
| Sep 30, 22 | 510.30 M Increased by +20.34% | -190.82 M Increased by +35.06% | Decreased by -37.39% Increased by +46.04% |
| Jun 30, 22 | 497.50 M Increased by +28.06% | -134.83 M Decreased by -59.42% | Decreased by -27.10% Decreased by -24.48% |
| Mar 31, 22 | 426.46 M Increased by +28.46% | -136.49 M Decreased by -12.41% | Decreased by -32.01% Increased by +12.49% |
| Dec 31, 21 | 429.85 M Decreased by -28.51% | -174.63 M Decreased by -204.51% | Decreased by -40.63% Decreased by -246.19% |